share_log

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376

Canaccord Genuity维持卖出福泰制药的评级,并将价格目标上调至376美元。
Benzinga ·  07/31 08:38  · 评级/大行评级

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sell and raises the price target from $371 to $376.

Canaccord Genuity分析师Whitney Ijem认为福泰制药(NASDAQ:VRTX)是卖出,并将价格目标从371美元上调至376美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发